share_log

藥明巨諾(02126.HK)倍諾達新適應症上市許可申請獲受理

AASTOCKS ·  Jan 4 13:39

藥明巨諾-B(02126.HK)公布,中國藥監局已受理靶向CD19的自體嵌合抗原受體細胞免疫治療產品倍諾達(瑞基奧侖賽注射液)用於治療復發或難治性套細胞淋巴瘤患者的新適應症上市許可申請。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment